Waheed Nadia 4

What Happened
Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, sold 14,828 shares of the company's common stock on June 3, 2026, for a weighted average price of $8.27, generating proceeds of approximately $122,628. This sale was not a discretionary trade but executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units vesting.

Key Details

• Transaction date: 2026-06-03 (Form 4 filed 2026-06-05). Filed timely.
• Type: Sale (sell-to-cover for tax withholding under an automatic instruction).
• Shares sold: 14,828; weighted average price: $8.27; total proceeds ≈ $122,628.
• Price range for the multiple executions: $8.2388 to $8.3000. Reporting person can provide per‑trade breakdown on request (footnote).
• Reason: Sell-to-cover election to satisfy tax withholding for RSUs vesting on June 1, 2026; instruction adopted June 1, 2024.
• Shares owned after transaction: Not disclosed in the provided filing.

Context
This was a routine, non-discretionary sell-to-cover to meet tax withholding on vested RSUs, which is common and does not by itself indicate the insider’s view on the company. The filing includes an offer to provide detailed per‑trade pricing within the reported range upon request.